Geode Capital Management LLC Sells 2,770 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)

Geode Capital Management LLC lessened its position in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) by 0.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 950,397 shares of the biotechnology company’s stock after selling 2,770 shares during the quarter. Geode Capital Management LLC owned about 1.68% of Astria Therapeutics worth $8,499,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in ATXS. JPMorgan Chase & Co. raised its position in shares of Astria Therapeutics by 39.6% during the 4th quarter. JPMorgan Chase & Co. now owns 54,664 shares of the biotechnology company’s stock valued at $489,000 after buying an additional 15,520 shares in the last quarter. Vanguard Group Inc. raised its position in Astria Therapeutics by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 2,677,353 shares of the biotechnology company’s stock valued at $23,936,000 after purchasing an additional 41,833 shares during the period. KLP Kapitalforvaltning AS bought a new stake in shares of Astria Therapeutics in the 4th quarter valued at approximately $41,000. American Century Companies Inc. boosted its holdings in shares of Astria Therapeutics by 9.9% in the 4th quarter. American Century Companies Inc. now owns 42,693 shares of the biotechnology company’s stock worth $382,000 after purchasing an additional 3,839 shares during the period. Finally, Teacher Retirement System of Texas bought a new position in shares of Astria Therapeutics during the 4th quarter valued at approximately $91,000. Institutional investors own 98.98% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on ATXS shares. JMP Securities started coverage on shares of Astria Therapeutics in a research note on Friday, January 31st. They set an “outperform” rating and a $26.00 price objective for the company. Wedbush reaffirmed an “outperform” rating and set a $28.00 price target (up from $27.00) on shares of Astria Therapeutics in a research note on Wednesday, March 12th. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research report on Tuesday, March 11th. Finally, Citizens Jmp raised shares of Astria Therapeutics to a “strong-buy” rating in a research note on Friday, January 31st. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Astria Therapeutics presently has a consensus rating of “Buy” and an average target price of $26.60.

Astria Therapeutics Trading Up 12.3 %

NASDAQ ATXS opened at $5.19 on Thursday. The stock has a market cap of $292.89 million, a PE ratio of -2.48 and a beta of 0.68. Astria Therapeutics, Inc. has a 12 month low of $3.56 and a 12 month high of $12.92. The company’s 50-day moving average price is $5.63 and its 200-day moving average price is $8.20.

Astria Therapeutics (NASDAQ:ATXS) last issued its earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.01. As a group, sell-side analysts forecast that Astria Therapeutics, Inc. will post -1.65 earnings per share for the current year.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.